UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2025
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
On October 6, 2025, NeuroSense Therapeutics Ltd.
issued a press release reporting that its drug candidate PrimeC produces statistically significant reductions in Alzheimer’s
disease biomarkers. A copy of the press release is furnished herewith as Exhibit 99.1.
Exhibit Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated October 6, 2025 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NeuroSense Therapeutics Ltd. |
| |
|
|
| Date: October 6, 2025 |
By: |
/s/ Alon Ben-Noon |
| |
|
Alon Ben-Noon |
| |
|
Chief Executive Officer |
